Barts Health NHS Trust

Running trials

• Not yet recruiting

  Diet-drive Gut Microbiome and Outcome in Patients With Early-stage Triple-negative Breast Cancer Undergoing Neoadjuvant Chemotherapy and Immunotherapy.

  NCT07551765· Barts & The London NHS Trust· Source

• Not yet recruiting

  Coronary Sinus Reducer Objective Impact on SymptoMs, Ischaemia and miCrovascular Resistance in Non-obstructive Hypertrophic CardioMyopathy

  NCT07865364· Imperial College London· Source

• Recruiting

  A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

  NCT07768189· Phase 3· Corbus Pharmaceuticals Inc.· Source

• Recruiting

  HCMR Re-Imaging Study

  NCT07054073· Christopher Kramer· Source

• Recruiting

  Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

  NCT07555938· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Hoffmann-La Roche· Source

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study

  NCT06987045· Queen Mary University of London· Source

• Recruiting

  A Study Evaluating the Performance of Using AI Software and Chest X-rays to Screen for Osteoporosis as Compared to Standard DXA Scans in Patients 50 Years and Older

  NCT07421713· Promedius Inc· Source

• Recruiting

  Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

  NCT07096778· Phase 2· CellCentric Ltd.· Source

• Recruiting

  Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

  NCT06954480· Phase 2· Queen Mary University of London· Source

• Recruiting

  Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

  NCT07116967· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

  NCT06486883· Phase 2· MedSIR· Source

• Recruiting

  New bioMarkers tO straTIfy cOlorectal caNcer Referrals

  NCT07035691· Queen Mary University of London· Source

• Recruiting

  Feasibility of a Tailored Online Self-compassion Intervention

  NCT07051005· Canterbury Christ Church University· Source

• Recruiting

  Artificial Intelligence-Assisted Magnetic Resonance Imaging for Quality, Efficiency and Equity in the National Health Service (NHS) Care of Multiple Sclerosis

  NCT07111637· Queen Mary University of London· Source

• Recruiting

  A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

  NCT06820463· Phase 2· AbbVie· Source

• Recruiting

  A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

  NCT06843447· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  NCT06819007· Phase 3· Daiichi Sankyo· Source

• Recruiting

  A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease

  NCT07363044· Alimentiv Inc.· Source

• Active, not recruiting

  Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer

  NCT06612203· Phase 1/2· MedSIR· Source

• Recruiting

  A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

  NCT06284317· Phase 3· ETOP IBCSG Partners Foundation· Source

• Active, not recruiting

  A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

  NCT06628310· Phase 2· AbbVie· Source

• Recruiting

  Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

  NCT06382948· Phase 3· MedSIR· Source

• Active, not recruiting

  Nipocalimab in Moderate to Severe Sjogren's Disease

  NCT06741969· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Cryoballoon/Radiofrequency/Pulsed Field Ablation of Atrial Fibrillation Versus Medical Treatment for Heart

  NCT06505798· University College, London· Source

• Enrolling by invitation

  REAl World Dementia OUTcomes: Observational Study

  NCT07238049· University of Oxford· Source

• Recruiting

  Nutrition and Clinical Outcomes in IBD

  NCT06550310· Barts & The London NHS Trust· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

  NCT06544499· Phase 3· argenx· Source

• Recruiting

  Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  NCT06548542· Phase 2· AbbVie· Source

• Active, not recruiting

  Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06564142· Phase 3· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Source

• Active, not recruiting

  A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

  NCT06564311· Phase 2· Zenas BioPharma (USA), LLC· Source

• Recruiting

  Cardio-Renal Registry

  NCT06521801· Queen Mary University of London· Source

• Recruiting

  A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

  NCT06428409· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

  NCT06320067· Phase 3· University College, London· Source

• Active, not recruiting

  Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis

  NCT06230354· Phase 2· Imperial College London· Source

• Active, not recruiting

  A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06254950· Phase 2· Takeda· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

  NCT06220201· Phase 1· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

  NCT06257875· Phase 2· AbbVie· Source

• Recruiting

  A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

  NCT06233461· Phase 2· Takeda· Source

• Recruiting

  The STOP-MED CTRCD Trial

  NCT06183437· Phase 4· Dinesh Thavendiranathan· Source

• Recruiting

  MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  NCT06152575· Phase 3· Pfizer· Source

• Active, not recruiting

  Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06029972· Phase 2· Gilead Sciences· Source

• Recruiting

  Barts Sex-CAD Database - Sex Hormones and Inflammatory Status in Coronary Artery Disease

  NCT06327984· Queen Mary University of London· Source

• Recruiting

  Early Discharge Pathway Registry

  NCT06040528· Queen Mary University of London· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

  NCT05968326· Phase 2· Genentech, Inc.· Source

• Recruiting

  A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT05730036· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

  NCT05968430· Phase 3· Mineralys Therapeutics Inc.· Source

• Active, not recruiting

  Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  NCT05701358· Population Health Research Institute· Source

• Recruiting

  A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  NCT05442567· Phase 3· Takeda· Source

Showing 50 of 96.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease7 recruiting
• Crohn's disease7 recruiting
• Colorectal cancer4 recruiting
• Metastatic breast cancer4 recruiting
• Atrial fibrillation3 recruiting
• Multiple myeloma3 recruiting
• Stroke3 recruiting
• Triple-negative breast cancer3 recruiting
• Ulcerative colitis3 recruiting
• Bladder cancer2 recruiting
• Heart failure2 recruiting
• Hypertrophic cardiomyopathy2 recruiting
• Osteoporosis2 recruiting
• Ovarian cancer2 recruiting
• Prostate cancer2 recruiting
• Alzheimer disease1 recruiting
• Chronic kidney disease1 recruiting
• Head and neck cancer1 recruiting
• HIV1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lung cancer1 recruiting
• Multiple sclerosis1 recruiting
• Osteoarthritis1 recruiting
• Pancreatic cancer1 recruiting
• Psoriasis1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Recruiting

  Study of WAL0921 in Patients With Glomerular Kidney Diseases

  NCT06466135· Phase 2· Walden Biosciences· Source

• Completed

  A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06049017· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Diagnostic Accuracy Study for OWL-EVO1 as a Lung Cancer EVOC® Probe (Evolution Phase 2)

  NCT06193239· Phase 2· Owlstone Ltd· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

  NCT05767346· Phase 3· Cytokinetics· Source

• Completed

  Assessment of Tool Placement in Pulmonary Nodule(s) Using a Robotic Navigational Bronchoscopy System

  NCT05867953· Intuitive Surgical· Source

• Completed

  Closing the Loop in People with Type 1 Diabetes

  NCT05653050· University of Cambridge· Source

• Completed

  A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom

  NCT05555979· AbbVie· Source

• Completed

  A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease.

  NCT05924243· Phase 1· Hoffmann-La Roche· Source

• Completed

  SCRATCH-HTN Study: Evaluating Autonomic Neuromodulation Using Trans-cutaneous Vagal Stimulation in Hypertensive Patients

  NCT05179343· Queen Mary University of London· Source

• Completed

  ADAs to Alemtuzumab

  NCT06310343· Queen Mary University of London· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Gilead Sciences· Source

• Completed

  A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

  NCT04919512· Phase 2· Janssen Research & Development, LLC· Source

• Terminated

  Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment

  NCT05435352· Ourotech, Inc.· Source

• Completed

  GOS to Reduce Symptom Severity in IBS

  NCT05157061· Clasado· Source

• Terminated

  Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

  NCT04778397· Phase 3· Gilead Sciences· Source

• Completed

  Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia

  NCT04864795· Vifor (International) Inc.· Source

• Completed

  A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma

  NCT04763408· Eisai Inc.· Source

• Completed

  PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

  NCT04870333· Phase 2/3· Cambridge University Hospitals NHS Foundation Trust· Source

• Completed

  Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

  NCT04626518· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

  NCT04626479· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Terminated

  Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

  NCT04218084· Phase 3· Pfizer· Source

• Completed

  Prevention of Dysrhythmias on the Cardiac Intensive Care Unit - Does Maintenance of High-normal Serum Potassium Levels Matter

  NCT04053816· Phase 3· Barts & The London NHS Trust· Source

• Completed

  First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC

  NCT04408118· Phase 2· MedSIR· Source

• Completed

  Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR

  NCT04295577· Royal Marsden NHS Foundation Trust· Source

• Completed

  Ustekinumab Real World Evidence Study

  NCT07748338· University Hospital Southampton NHS Foundation Trust· Source

• Completed

  Quantitative Sensory Testing and Occipital Nerve Stimulator

  NCT06022848· Barts & The London NHS Trust· Source

• Completed

  Oral Cladribine B-cell Study

  NCT06415864· Queen Mary University of London· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source

• Completed

  Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

  NCT04054362· Phase 2· Barts & The London NHS Trust· Source

• Completed

  A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

  NCT03734016· Phase 3· BeiGene· Source

• Completed

  Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

  NCT03569293· Phase 3· AbbVie· Source

• Completed

  A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

  NCT03607422· Phase 3· AbbVie· Source

• Terminated

  Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

  NCT03573882· Phase 3· Pfizer· Source

• Completed

  Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

  NCT03391466· Phase 3· Kite, A Gilead Company· Source

• Completed

  A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

  NCT03332017· Phase 2· BeiGene· Source

• Completed

  Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

  NCT03112174· Phase 3· Pharmacyclics LLC.· Source

• Completed

  A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

  NCT03104374· Phase 3· AbbVie· Source

• Completed

  Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2

  NCT02733159· Phase 2· University of Birmingham· Source

• Terminated

  TITAN™ Reverse Shoulder System

  NCT02204228· Smith & Nephew, Inc.· Source

• Completed

  PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer

  NCT02423603· Phase 2· Queen Mary University of London· Source

• Completed

  Development of an AF Specific Quality of Life Questionnaire: AF-PROMS

  NCT06731543· Barts & The London NHS Trust· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Multiple sclerosis39 works · 6 trials
• Coronary artery disease31 works · 11 trials
• Crohn's disease30 works · 8 trials
• Ulcerative colitis24 works · 9 trials
• Atopic dermatitis (eczema)17 works · 3 trials
• Endometrial cancer14 works · 0 trials
• Hidradenitis suppurativa8 works · 0 trials